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A B S T R A C T
Purpose: In vitro or in animal models of epilepsy, ghrelin showed a clear anticonvulsant action, whose
mechanisms are somewhat obscure. In humans however, a controversial relation exists between ghrelin
and epilepsy. Yet most studies investigated just total ghrelin levels, without a proper distinction
between acylated (AG) or unacylated ghrelin (UAG). We thus evaluated separately AG and UAG interictal
levels in adult patients with epilepsy, and their relation to clinical features.
Method: Cross-sectional study in a tertiary referral centre. Fifty-six patients were recruited: 19 with
idiopathic generalized epilepsy, 18 with cryptogenic focal epilepsy and 19 with symptomatic focal
epilepsy. Twenty-six healthy subjects of similar age, sex and body mass index (BMI) acted as controls. AG
and UAG levels were measured following an overnight fasting and contrasted to the clinical and
biometric features.
Results: AG and UAG levels were similar between patients and controls. The AG/UAG ratio was higher in
patients, also when weighted for covariates (age, BMI, gender, and drugs). Splitting patients according to
their epileptic syndrome, drug-resistance or antiepileptic drug number/type resulted in no signiﬁcant
difference in AG, UAG or their ratio. Yet, AG and UAG levels were positively predicted by disease duration,
independently by confounders.
Conclusion: In adult patients with epilepsy, interictal ghrelin levels did not differ from controls, though
the AG/UAG ratio was imbalanced. Interpretation of the latter phenomenon is uncertain. Further, levels
of AG and UAG were in direct proportion to disease duration, which may represent a long-term
compensatory mechanism, antagonistic to the epileptic process.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Ghrelin is a 28-amino acid neuropeptide discovered as the
endogenous ligand of the growth hormone secretagogue receptor
type 1a (GHS-R1a), which stimulates the release of growth
hormone by the pituitary gland.1–3 It acts as an orexigenic peptide
promoting appetite, food intake, body weight gain and adipogen-
esis.4,5 Ghrelin is produced mainly by the X/A-like cells of the
oxyntic stomach mucosa and circulates in the bloodstream in two
forms. Acylated ghrelin (AG) bears an acylation on the Ser3 residue,
that is essential for its endocrine activities, particularly its
activation of the GHS-R1a.6 Unacylated (often termed desacylated)* Corresponding author at: Department of Translational Medicine, Section of
Neurology, University of Piemonte Orientale ‘‘A. Avogadro’’, Corso Mazzini 18,
28100 Novara, Italy. Tel.: +39 03213733767.
E-mail address: gionata.strigaro@gmail.com (G. Strigaro).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reghrelin (UAG) was thought not to bind to the GHSR-1a. Still it
exerts metabolic, cardiovascular, and antiproliferative effects,
probably by binding to different GHS-R subtypes.6,7 However,
some recent studies suggest that high doses of UAG are agonist to
the GHS-R1a, at least at central nervous system (CNS) sites.8 The
discovery of the enzyme which octanoylates ghrelin, i.e. ghrelin
O-acyltransferase (GOAT), has made the system more intriguing.9
In addition to the pituitary gland, the GHSR-1a can be found
in various CNS regions, especially the hippocampus and the
hypothalamus.10,11 Probably, this widespread localization
accounts for the multiple functions of ghrelin. In fact, apart from
its endocrine aspects, ghrelin is also implied in memory, learning
and sleep. Studies performed in vitro or in animal models of
epilepsy ascribed to ghrelin clear antiepileptic properties, though
the mechanisms would be somewhat obscure.12–15 This triggered
investigations on ghrelin in human epilepsy, but, to date, ﬁndings
are rather contradictory. Several studies observed higher ghrelin
levels, but others showed lower levels in patient groups differingserved.
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correlation with drug-resistant epilepsy has never been reported.
However, most studies investigated just total ghrelin in the
interictal period, which may not reﬂect the actual circulating
distribution of AG and UAG.16
The primary aim of this study was to evaluate separately AG and
UAG interictal levels in a cohort of adult patients with epilepsy
treated with antiepileptic drugs (AEDs) compared with healthy
subjects. The secondary aim was to identify if those levels were
associated with any clinical features of the epileptic syndrome.
2. Methods
2.1. Subjects
Fifty-six adult consecutive outpatients (Table 1) were recruited
at the Epilepsy Clinic of the Department of Neurology of the
University of Piemonte Orientale and participated in this cross-
sectional study, over a 6-month period (January 2013–June 2013).
The diagnosis of epilepsy was made on the basis of the clinical
history, imaging, and electroencephalography (EEG) ﬁndings by
two experienced epileptologists not involved in the present study,
according to the ILAE criteria.17We included patients older than 18
years, with a deﬁnite diagnosis since at least one year, who had no
AED change in the past month. Metabolic inclusion criteria were: a
BMI <30 kg/m2, total cholesterol <200 mg/dl, triglycerides
<200 mg/dl, glucose level <126 mg/dl. Further criteria were no
evidence of gastrointestinal, endocrine or chronic illness. Female
patients were recruited if they had a normal menstrual cycle, and
their blood samples were collected in the follicular phase. Females
on oestrogen therapy were excluded. Written informed consent
was obtained from all subjects. Twenty-six healthy volunteers of
similar age, sex and metabolic proﬁle were recruited as controls
(Table 1). The experimental procedures were approved by the
‘‘Maggiore della Carita`’’ Hospital Ethics Committee and were
performed in accordance with the Declaration of Helsinki.
The subject height was measured by the Harpenden stadiometer,
and weight by an electronic scale. BMI was calculated as body weight
divided by squared height (kg/m2). The lipid proﬁle (cholesterol and
triglycerides) and glucose levels were determined as well. Fasting
AG and UAG levels in all subjects and circulating drug levels in
patients were evaluated at 8.00–8.30 a.m. following an overnight
fasting. Blood plasma samples for AG e UAG measures wereTable 1
Clinical and biometric data of patients and controls.
Epileptic syndrome Patients Controls
IGE CFE SFE
# 19 18 19 26
Gender (%)
Men 63.2 50.0 52.6 53.8
Women 36.8 50.0 47.4 46.2
Age, years (SEM) 33.9 (2.6) 42.5 (2.5) 46.3 (3.5) 36.4 (2.2)
BMI (kg/m2) (SEM) 24.9 (0.7) 24.6 (0.8) 22.2 (0.7) 22.3 (0.7)
Disease duration
(SEM)
16.3 (2.9) 13.9 (2.7) 15.6 (3.6) –
Seizure frequency (%)
Seizure-free 94.7 83.3 26.3 –
<1/month 5.3 5.6 21.1
1/month – 11.1 52.6
Treatment (%)
1 drug 84.2 77.8 42.1 –
2 drugs 15.8 22.2 36.8
3 drugs – – 21.1
IGE, idiopathic generalized epilepsy; CFE, cryptogenic focal epilepsy; SFE,
symptomatic focal epilepsy; BMI, body mass index.collected in tubes containing EDTA and a protease inhibitor
(pepstatin A 10 mM), centrifuged at 3000 rpm for 15 min (tempera-
ture = 4 8C), then supernatans were stored at 20 8C. Samples for AG
determination were also added of 1 mM of p-hydroxymercuriben-
zoic acid (PHMB) to prevent AG degradation by protease, acidiﬁed by
the addition of 1 N HCl,18 then stored at 80 8C. AG and UAG levels,
expressed in pg/ml, were measured separately by ELISA kits in
according to the manufacturer’s instructions (BioVendor – Labor-
atorni Medicina a.s., Brno, Czech Republic). Sensitivity was 0.8 pg/ml
and 0.6 pg/ml for AG and UAG, respectively.
2.2. Statistics
Biometric and biochemical data were expressed as mean
value  SEM. Initially, non-parametric Wilcoxon–Mann–Whitney
tests were used to compare crude means. Correlation of AG and
UAG levels with continuous clinical and biochemical measures was
examined using Pearson coefﬁcients. The distribution of continuous
variables was then examined for skewness, and was logarithmically
transformed where appropriate, to perform an analysis of covariance
(ANCOVA). ANCOVA was used to determine differences among
groups. Covariates were age, gender, and BMI. The stepwise linear
regression model with two-tailed probability values and 95%
conﬁdence intervals ﬁnally measured the strength of the association
between AG and UAG (dependent variables) and gender, age, BMI,
disease duration or seizure frequency, number and type of AEDs
(independent variables). A sample of 18 individuals for each group
(patients and controls) was estimated to be sufﬁcient to demonstrate
a difference of 22 pg/ml in AG with a SD of 20 with 90% power and a
signiﬁcance level of 95%, using the Student’s t-test. AG was used
because it has the wider standard deviation in literature. Statistical
signiﬁcance was assumed as p < 0.05 and Bonferroni corrections for
multiple comparisons were used. All statistical analyses were
performed with the SPSS program for Windows, version 17.0 (SPSS
Inc.; Chicago, IL, USA).
3. Results
Table 1 summarizes the subject clinical and biometric data.
Patients with IGE were younger than the other groups (p < 0.01).
Of the symptomatic focal epilepsy (SFE) patients, the majority
(13/19) presented with temporal lobe epilepsy (TLE) and 7 were
diagnosed with hippocampal sclerosis. Thirty-eight patients were
seizure-free on a monotherapy, whereas 18 were drug-resistant
according to the current deﬁnition.19 The proportion of seizure-
free patients was signiﬁcantly (p < 0.01) smaller, and that of
patients with monthly seizures was signiﬁcantly (p < 0.01) larger
in the SFE group as compared to the rest. Of the drug-resistant
patients, 14 were on 2 AEDs, while 4 were on 3 or more AEDs. As to
monotherapy, the most common drug was carbamazepine (CBZ)
(n = 14), followed by valproate (VPA) (n = 12).
Overall, AG and UAG levels were similar between patients
(AG = 12.4  5.3 pg/ml; UAG = 231.6  37.5 pg/ml) and controls
(AG = 7.4  2.1 pg/ml; UAG = 196.0  37.3 pg/ml). The AG/UAG ratio
was higher in patients than in controls (3.7  0.8 vs 2.4  0.4;
p < 0.02). This ﬁnding remained signiﬁcant even when weighted
for BMI, age and gender (unstandard B: 0.200  0.089, 95% CI
0.022–0.378; b: 0.287, p < 0.02).
Splitting patients according to their epilepsy diagnosis, drug-
resistance (AG, p = 0.405; UAG, p = 0.129; AG/UAG, p = 0.369) and
AED number (AG, p = 0.133; UAG, p = 0.597; AG/UAG, p = 0.368)
resulted in no signiﬁcant difference in the levels of AG, UAG or their
ratio (Table 2). Considering monotherapy patients, values of AG
and UAG were similar in both the CBZ (AG = 8.8  2.2 and
UAG = 241.7  81.2 pg/ml) and the VPA subgroup (AG = 9.5  3.0
and UAG = 186.4  22.4 pg/ml).
Table 2
Acylated (AG) and unacylated (UAG) ghrelin levels in patients, according to the epileptic syndrome, drug resistance and number of antiepileptic drugs (AEDs).
Epileptic syndrome Drug resistance # of AEDs
IGE CFE SFE Yes No 1 2 >2
# 19 18 19 18 38 38 14 4
Ghrelin (pg/ml)
AG 8.2  2.2 21.9  13.9 6.8  2.0 25.5  18.6 7.9  1.3 8.3  1.4 31.6  24.7 10.5  3.4
UAG 250.8  57.7 238.7  95.3 207.4  34.1 291.0  94.6 204.4  32.8 199.6  31.4 356.0  120.0 108.9  34.3
No signiﬁcant difference in the levels of AG, UAG or their ratio between these groups was detected. Data are expressed as mean  standard error of the mean (SEM).
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independent from sex, age, and BMI (r: 0.351, r2: 0.124; unstandard
B: 0.015  0.007, 95% CI 0.001–0.029; p < 0.01). The same was true
for UAG levels (r: 0.433, r2: 0.188; unstandard B: 0.008  0.004, 95% IC
0.001–0.015; p < 0.02).
4. Discussion
We report that interictal AG and UAG plasma levels in adult
patients with various epilepsy forms were not different from those
of healthy controls of similar age, sex and BMI. Still, the AG/UAG
ratio was signiﬁcantly (p < 0.02) higher in the population suffering
from epilepsy. Finally, AG and UAG levels increased signiﬁcantly
(p < 0.02) in proportion to disease duration.
The recent literature on ghrelin and epilepsy is controversial.
Berilgen et al.,20 found higher levels of total ghrelin in patients,
both with focal and generalized epilepsy. On the contrary, Dag
et al.,21 found reduced levels of total ghrelin in serum and
saliva. Similarly, Aydin et al.,22 reported on lower AG and UAG
levels (in serum and saliva). However, UAG levels were
calculated by subtracting AG from the total ghrelin, whereas
in the present study the two forms were measured separately.
Later, Aydin et al.,23 conﬁrmed their previous data in a cohort of
patients in the immediate postictal period and after AED
withdrawal. They found that changes in the two forms were
time-dependent. These contrasting results could be based on
heterogeneous patient features and antiepileptic treatment,
different epilepsy phase (postictal vs interictal), or measure-
ment techniques (e.g. saliva vs serum or calculated vs measured
levels). Contradictory results were also obtained in paediatric
populations, possibly because of additional confounding factors
such as the modulation of ghrelin secretion by pubertal stage,
age, weight gain or drug effects.16
At variance with other Authors we observed similar UAG and
AG levels in patients and controls. Since we analyzed separately
the two ghrelin species, we however might have depicted the
(patho) physiology of the system more accurately than previous
studies. Interestingly, we disclosed a higher AG/UAG ratio in
patients, also when weighted for confounders. This suggests that
the two forms may be imbalanced in epilepsy, as also shown in
other pathologic circumstances such as the metabolic syndrome,
type 1 diabetes, neonates and short post-feeding conditions.24–26
Since both forms of ghrelin are biologically active and might
interact, the AG/UAG ratio might represent a more reliable
parameter than the respective levels on their own.27 However,
the biological signiﬁcance of the ratio and its imbalance in epilepsy
remains to be clariﬁed.
The AED type did not inﬂuence ghrelin levels, at least in the two
subgroups analyzed (VPA vs CBZ). This is somewhat in contrast to
previous studies, since for instance ghrelin levels were increased in
children treated with VPA in prepubertal (but not in pubertal)
status.28,29 Yet, Greco et al.,30 found lower ghrelin levels in
pubertal subjects who signiﬁcantly gained weight during VPA
treatment. However, if very young prepubertal children wereconsidered separately, total ghrelin levels were decreased prior to/
independent of a consistent weight gain while on CBZ and VPA.31
The present study has some limitations that need to be
considered. First, all patients were treated with AEDs because of
ethical constraints. This represents an important confounding
factor and the ideal study should involve drug-naı¨ve patients.16
When ghrelin was measured in such patients, either with newly
diagnosed IGE 22 or in the post-ictal period,23 serum levels were
lower compared with controls,23 conﬁrming evidence from animal
models of epilepsy.12 The second limitation was the sample size
and the lack of statistical power with risk of false negative results,
which possibly prevented detection of changes in the ghrelin levels
among subgroups, especially between patients with and without
drug-resistant epilepsy.
Still we consider it a valuable ﬁnding that disease duration
signiﬁcantly (p < 0.02) predicted UAG and AG levels. Pearson
coefﬁcients (UAG, r = 0.433; AG, r = 0.351) suggest a moderate
positive association. Thus, ghrelin contribution to disease duration
might not be direct and exclusive, but other factors with stronger
association might be involved. However, we would speculate that
disease duration basically represents the duration of the ongoing
epileptogenic process, producing an imbalance between excitatory
and inhibitory circuits, and possibly a longer exposure to drugs. If
the anticonvulsant effects of ghrelin are mediated by GABA, the
main inhibitory neurotransmitter,13,32 higher levels of ghrelin
would be required as a long-term compensatory mechanism,
favouring neural inhibition.
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